staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad

Company profile
Ticker
STAA
Exchange
Website
CEO
Caren Mason
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
STAAR SURGICAL COMPANY
SEC CIK
Corporate docs
Subsidiaries
STAAR Surgical UK LTD • STAAR Surgical AG • STAAR Japan Inc. • STAAR Surgical PTE. LTD • Technology (Shanghai) Co., LTD • CO., LTD • STAAR Surgical India Private Limited ...
IRS number
953797439
STAA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
7 Jun 23
8-K
Regulation FD Disclosure
6 Jun 23
8-K
Regulation FD Disclosure
4 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
8-K
STAAR Surgical Reports First Quarter 2023 Results
3 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
8-K
Departure of Directors or Certain Officers
29 Mar 23
8-K
Regulation FD Disclosure
14 Mar 23
Transcripts
STAA
Earnings call transcript
2023 Q1
3 May 23
STAA
Earnings call transcript
2022 Q4
21 Feb 23
STAA
Earnings call transcript
2022 Q3
2 Nov 22
STAA
Earnings call transcript
2022 Q2
11 Aug 22
STAA
Earnings call transcript
2022 Q1
4 May 22
STAA
Earnings call transcript
2021 Q4
24 Feb 22
STAA
Earnings call transcript
2021 Q3
4 Nov 21
STAA
Earnings call transcript
2021 Q2
5 Aug 21
STAA
Earnings call transcript
2021 Q1
6 May 21
STAA
Earnings call transcript
2020 Q4
25 Feb 21
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Jan 21 | Jan 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89.97 mm | 89.97 mm | 89.97 mm | 89.97 mm | 89.97 mm | 89.97 mm |
Cash burn (monthly) | (no burn) | 8.59 mm | (no burn) | (no burn) | 1.70 mm | (no burn) |
Cash used (since last report) | n/a | 20.01 mm | n/a | n/a | 3.96 mm | n/a |
Cash remaining | n/a | 69.95 mm | n/a | n/a | 86.01 mm | n/a |
Runway (months of cash) | n/a | 8.1 | n/a | n/a | 50.7 | n/a |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 245 |
Opened positions | 34 |
Closed positions | 60 |
Increased positions | 74 |
Reduced positions | 97 |
13F shares | Current |
---|---|
Total value | 3.01 tn |
Total shares | 57.06 mm |
Total puts | 275.30 k |
Total calls | 455.90 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Broadwood Capital | 8.78 mm | $561.68 bn |
Broadwood Partners | 8.59 mm | $0.00 |
BLK Blackrock | 5.85 mm | $374.27 bn |
Vanguard | 5.13 mm | $327.92 bn |
Baillie Gifford & Co | 5.12 mm | $327.70 bn |
Anatole Investment Management | 2.04 mm | $130.63 bn |
STT State Street | 1.68 mm | $107.64 bn |
Palo Alto Investors | 1.35 mm | $86.16 bn |
Geneva Capital Management | 957.86 k | $61.25 bn |
Geode Capital Management | 941.61 k | $60.22 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Jun 23 | Patrick F. Williams | Common Stock | Payment of exercise | Dispose F | No | No | 54.79 | 1,987 | 108.87 k | 45,400 |
6 Jun 23 | Patrick F. Williams | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,121 | 0.00 | 47,387 |
8 May 23 | Warren Foust | Common Stock | Option exercise | Acquire M | No | No | 0 | 20,331 | 0.00 | 20,331 |
8 May 23 | Warren Foust | Common Stock Options Common Stock | Option exercise | Acquire M | No | No | 67.63 | 37,567 | 2.54 mm | 37,567 |
8 May 23 | Magda Michna | Common Stock | Option exercise | Acquire M | No | No | 0 | 14,047 | 0.00 | 14,047 |
8 May 23 | Magda Michna | Common Stock Options Common Stock | Option exercise | Acquire M | No | No | 67.63 | 25,955 | 1.76 mm | 25,955 |
News
Top 5 Health Care Stocks That Are Set To Fly In Q2
9 Jun 23
Canaccord Genuity Reiterates Buy on Staar Surgical, Maintains $77 Price Target
8 Jun 23
STAAR Surgical Revises Strategy Amid Slow U.S. Adoption, Analyst Adjusts Rating to Market Perform
7 Jun 23
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
7 Jun 23
William Blair Downgrades Staar Surgical to Market Perform
7 Jun 23
Press releases
EVO ICL Sponsors Jonas Brothers' The Tour
4 May 23
STAAR Surgical Reports First Quarter 2023 Results
3 May 23
STAAR Surgical to Report First Quarter Results on May 3, 2023
19 Apr 23
STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer
29 Mar 23